Similarly, Khanlari et al., in a study of 51 BPDCN patients, demonstrated that the presence of bone marrow clonal hematopoiesis, including cases with TET2 mutations, was associated with significantly inferior survival compared to those without such findings [31]. Here, TET2 is linked to CD4+/CD56+ hematodermic neoplasm.